Key clinical point: Treatment with interferon (IFN)-beta 1A improved the SARS-CoV-2-mRNA vaccine-specific humoral response in patients with multiple sclerosis (MS), which was significantly reduced in patients treated with cladribine, fingolimod, or ocrelizumab.

Major finding: Antispike immunoglobulin (Ig)G levels were significantly higher in IFN-treated patients with MS vs healthy controls (median, 1,916 vs 1,089; P = .029); however, antispike IgG levels were significantly lower in patients treated with cladribine (P = .002), fingolimod (P < .0001), or ocrelizumab (P < .0001).

Study details: This was a prospective monocentric study involving 149 patients with MS treated with disease-modifying therapies who were age- and gender-matched to 26 healthy controls, all of whom had no history of SARS-CoV-2 infection and received 2 doses of BNT162b2-mRNA COVID-19 vaccine.

Disclosures: This study was supported by Fondazione Italiana Sclerosi Multipla and others. The authors declared no conflict of interests.

Source: Maniscalco GT et al. Mult Scler Relat Disord. 2021 Dec 18. doi: 10.1016/j.msard.2021.103455.

Key clinical point: Treatment with interferon (IFN)-beta 1A improved the SARS-CoV-2-mRNA vaccine-specific humoral response in patients with multiple sclerosis (MS), which was significantly reduced in patients treated with cladribine, fingolimod, or ocrelizumab.

Major finding: Antispike immunoglobulin (Ig)G levels were significantly higher in IFN-treated patients with MS vs healthy controls (median, 1,916 vs 1,089; P = .029); however, antispike IgG levels were significantly lower in patients treated with cladribine (P = .002), fingolimod (P < .0001), or ocrelizumab (P < .0001).

Study details: This was a prospective monocentric study involving 149 patients with MS treated with disease-modifying therapies who were age- and gender-matched to 26 healthy controls, all of whom had no history of SARS-CoV-2 infection and received 2 doses of BNT162b2-mRNA COVID-19 vaccine.

Disclosures: This study was supported by Fondazione Italiana Sclerosi Multipla and others. The authors declared no conflict of interests.

Source: Maniscalco GT et al. Mult Scler Relat Disord. 2021 Dec 18. doi: 10.1016/j.msard.2021.103455.

Key clinical point: Treatment with interferon (IFN)-beta 1A improved the SARS-CoV-2-mRNA vaccine-specific humoral response in patients with multiple sclerosis (MS), which was significantly reduced in patients treated with cladribine, fingolimod, or ocrelizumab.

Major finding: Antispike immunoglobulin (Ig)G levels were significantly higher in IFN-treated patients with MS vs healthy controls (median, 1,916 vs 1,089; P = .029); however, antispike IgG levels were significantly lower in patients treated with cladribine (P = .002), fingolimod (P < .0001), or ocrelizumab (P < .0001).

Study details: This was a prospective monocentric study involving 149 patients with MS treated with disease-modifying therapies who were age- and gender-matched to 26 healthy controls, all of whom had no history of SARS-CoV-2 infection and received 2 doses of BNT162b2-mRNA COVID-19 vaccine.

Disclosures: This study was supported by Fondazione Italiana Sclerosi Multipla and others. The authors declared no conflict of interests.

Source: Maniscalco GT et al. Mult Scler Relat Disord. 2021 Dec 18. doi: 10.1016/j.msard.2021.103455.

Key clinical point: Discontinuation of natalizumab seemed safe in patients with multiple sclerosis (MS), who converted to secondary MS during treatment, with a high annual relapse rate (ARR) before natalizumab treatment being a risk factor for early relapse posttreatment discontinuation.

Major finding: After natalizumab discontinuation, conversion to secondary MS during treatment was protective for disease reactivation (odds ratio [OR], 0.08; P = .03), whereas ARR before treatment was the only risk factor for early relapse (OR, 1.46; P = .014).

Study details: This was a retrospective analysis of 235 patients with MS who were treated with natalizumab, of whom 105 discontinued the treatment.

Disclosures: No information on funding was provided. E Fava reported no conflict of interests, and the other authors reported receiving fees for acting as an advisor/speaker/consultant or receiving grants for travel/research from various sources.

Source: Auer M et al. Sci Rep. 2021 Dec 2. doi: 10.1038/s41598-021-02665-6.

Key clinical point: Discontinuation of natalizumab seemed safe in patients with multiple sclerosis (MS), who converted to secondary MS during treatment, with a high annual relapse rate (ARR) before natalizumab treatment being a risk factor for early relapse posttreatment discontinuation.

Major finding: After natalizumab discontinuation, conversion to secondary MS during treatment was protective for disease reactivation (odds ratio [OR], 0.08; P = .03), whereas ARR before treatment was the only risk factor for early relapse (OR, 1.46; P = .014).

Study details: This was a retrospective analysis of 235 patients with MS who were treated with natalizumab, of whom 105 discontinued the treatment.

Disclosures: No information on funding was provided. E Fava reported no conflict of interests, and the other authors reported receiving fees for acting as an advisor/speaker/consultant or receiving grants for travel/research from various sources.

Source: Auer M et al. Sci Rep. 2021 Dec 2. doi: 10.1038/s41598-021-02665-6.

Key clinical point: Discontinuation of natalizumab seemed safe in patients with multiple sclerosis (MS), who converted to secondary MS during treatment, with a high annual relapse rate (ARR) before natalizumab treatment being a risk factor for early relapse posttreatment discontinuation.

Major finding: After natalizumab discontinuation, conversion to secondary MS during treatment was protective for disease reactivation (odds ratio [OR], 0.08; P = .03), whereas ARR before treatment was the only risk factor for early relapse (OR, 1.46; P = .014).

Study details: This was a retrospective analysis of 235 patients with MS who were treated with natalizumab, of whom 105 discontinued the treatment.

Disclosures: No information on funding was provided. E Fava reported no conflict of interests, and the other authors reported receiving fees for acting as an advisor/speaker/consultant or receiving grants for travel/research from various sources.

Source: Auer M et al. Sci Rep. 2021 Dec 2. doi: 10.1038/s41598-021-02665-6.

Key clinical point: COVID-19 vaccines are safe and elicit a protective humoral response in most patients with multiple sclerosis (MS) who were treated with disease-modifying treatments (DMTs) or remained untreated, except for some patients treated with fingolimod or ocrelizumab.

Major finding: Overall, 86.8% of patients developed a positive humoral response against SARS-CoV-2, with only some patients treated with fingolimod (22.2%) or ocrelizumab (66%) failing to produce a significant humoral response (P < .01). Moreover, immunoglobulin G levels against SARS-CoV2 were significantly lower in patients treated with fingolimod or ocrelizumab than those treated with other DMTs or those who remained untreated (P < .01). None of the patients experienced any adverse events requiring hospitalization.

Study details: This was a prospective cohort study involving 140 patients with MS who were treated with different DMTs and had received vaccination for COVID-19 (mostly BNT162b2).

Disclosures: No source of funding was declared.

Source: Capone F et al. Neurotherapeutics. 2021 Dec 3. doi: 10.1007/s13311-021-01165-9.

Key clinical point: COVID-19 vaccines are safe and elicit a protective humoral response in most patients with multiple sclerosis (MS) who were treated with disease-modifying treatments (DMTs) or remained untreated, except for some patients treated with fingolimod or ocrelizumab.

Major finding: Overall, 86.8% of patients developed a positive humoral response against SARS-CoV-2, with only some patients treated with fingolimod (22.2%) or ocrelizumab (66%) failing to produce a significant humoral response (P < .01). Moreover, immunoglobulin G levels against SARS-CoV2 were significantly lower in patients treated with fingolimod or ocrelizumab than those treated with other DMTs or those who remained untreated (P < .01). None of the patients experienced any adverse events requiring hospitalization.

Study details: This was a prospective cohort study involving 140 patients with MS who were treated with different DMTs and had received vaccination for COVID-19 (mostly BNT162b2).

Disclosures: No source of funding was declared.

Source: Capone F et al. Neurotherapeutics. 2021 Dec 3. doi: 10.1007/s13311-021-01165-9.

Key clinical point: COVID-19 vaccines are safe and elicit a protective humoral response in most patients with multiple sclerosis (MS) who were treated with disease-modifying treatments (DMTs) or remained untreated, except for some patients treated with fingolimod or ocrelizumab.

Major finding: Overall, 86.8% of patients developed a positive humoral response against SARS-CoV-2, with only some patients treated with fingolimod (22.2%) or ocrelizumab (66%) failing to produce a significant humoral response (P < .01). Moreover, immunoglobulin G levels against SARS-CoV2 were significantly lower in patients treated with fingolimod or ocrelizumab than those treated with other DMTs or those who remained untreated (P < .01). None of the patients experienced any adverse events requiring hospitalization.

Study details: This was a prospective cohort study involving 140 patients with MS who were treated with different DMTs and had received vaccination for COVID-19 (mostly BNT162b2).

Disclosures: No source of funding was declared.

Source: Capone F et al. Neurotherapeutics. 2021 Dec 3. doi: 10.1007/s13311-021-01165-9.

Key clinical point: Between 2005 and 2019, sorafenib therapy has led to improvement in clinical outcomes among treatment-naïve patients with advanced hepatocellular carcinoma (HCC) in concurrence with a decrease in the median duration of therapy.

Main finding: While the median duration of therapy decreased by 53%, from 23.1 weeks to 12.2 weeks (P = .003) over the study period, the median overall survival increased by 4.5 months (P = .048) and the objective response rate increased by 6 months (P = .003).

Study details: This was an analysis of 16 randomized clinical trials (9 phase 3 and 7 phase 2) conducted from 2005-2019, wherein sorafenib was administered to 4,086 patients with advanced HCC naïve to systemic therapy to compare its effect relative to another systemic therapy or placebo.

Disclosures: The study received grants from the National Institutes of Health. M Yarchoan declared receiving research grants from or working as a consultant for various organizations.

Source: Brown TJ et al. Gastrointest Tumors. 2021 Dec 22. doi: 10.1159/000521625.

Key clinical point: Between 2005 and 2019, sorafenib therapy has led to improvement in clinical outcomes among treatment-naïve patients with advanced hepatocellular carcinoma (HCC) in concurrence with a decrease in the median duration of therapy.

Main finding: While the median duration of therapy decreased by 53%, from 23.1 weeks to 12.2 weeks (P = .003) over the study period, the median overall survival increased by 4.5 months (P = .048) and the objective response rate increased by 6 months (P = .003).

Study details: This was an analysis of 16 randomized clinical trials (9 phase 3 and 7 phase 2) conducted from 2005-2019, wherein sorafenib was administered to 4,086 patients with advanced HCC naïve to systemic therapy to compare its effect relative to another systemic therapy or placebo.

Disclosures: The study received grants from the National Institutes of Health. M Yarchoan declared receiving research grants from or working as a consultant for various organizations.

Source: Brown TJ et al. Gastrointest Tumors. 2021 Dec 22. doi: 10.1159/000521625.

Key clinical point: Between 2005 and 2019, sorafenib therapy has led to improvement in clinical outcomes among treatment-naïve patients with advanced hepatocellular carcinoma (HCC) in concurrence with a decrease in the median duration of therapy.

Main finding: While the median duration of therapy decreased by 53%, from 23.1 weeks to 12.2 weeks (P = .003) over the study period, the median overall survival increased by 4.5 months (P = .048) and the objective response rate increased by 6 months (P = .003).

Study details: This was an analysis of 16 randomized clinical trials (9 phase 3 and 7 phase 2) conducted from 2005-2019, wherein sorafenib was administered to 4,086 patients with advanced HCC naïve to systemic therapy to compare its effect relative to another systemic therapy or placebo.

Disclosures: The study received grants from the National Institutes of Health. M Yarchoan declared receiving research grants from or working as a consultant for various organizations.

Source: Brown TJ et al. Gastrointest Tumors. 2021 Dec 22. doi: 10.1159/000521625.

Key clinical point: Having undergone drug-eluting bead transarterial chemoembolization (DEB-TACE), treatment response and disease-free survival (DFS) in patients with hepatocellular carcinoma (HCC) could be predicted by MRI signal intensity in the hepatobiliary phase (HBP) and serum alpha-fetoprotein (AFP) levels, respectively.

Main finding: The only significant predictive factors of noncomplete response and short DFS were signal intensity heterogeneity in the HBP (adjusted odds ratio, 4.807; P = .048) and elevated serum AFP levels (≥30 ng/mL; adjusted hazard ratio, 2.916; P = .040), respectively.

Study details: This was a preliminary single-center retrospective study including 55 treatment-naive patients who underwent DEB-TACE for HCC.

Disclosures: The study was sponsored by the Bio & Medical Technology Development Program of the National Research Foundation funded by the Korean government. The authors reported no conflict of interests.

Source: Lee JY et al. Sci Rep. 2021 Dec 15. doi: 10.1038/s41598-021-01839-6.

Key clinical point: Having undergone drug-eluting bead transarterial chemoembolization (DEB-TACE), treatment response and disease-free survival (DFS) in patients with hepatocellular carcinoma (HCC) could be predicted by MRI signal intensity in the hepatobiliary phase (HBP) and serum alpha-fetoprotein (AFP) levels, respectively.

Main finding: The only significant predictive factors of noncomplete response and short DFS were signal intensity heterogeneity in the HBP (adjusted odds ratio, 4.807; P = .048) and elevated serum AFP levels (≥30 ng/mL; adjusted hazard ratio, 2.916; P = .040), respectively.

Study details: This was a preliminary single-center retrospective study including 55 treatment-naive patients who underwent DEB-TACE for HCC.

Disclosures: The study was sponsored by the Bio & Medical Technology Development Program of the National Research Foundation funded by the Korean government. The authors reported no conflict of interests.

Source: Lee JY et al. Sci Rep. 2021 Dec 15. doi: 10.1038/s41598-021-01839-6.

Key clinical point: Having undergone drug-eluting bead transarterial chemoembolization (DEB-TACE), treatment response and disease-free survival (DFS) in patients with hepatocellular carcinoma (HCC) could be predicted by MRI signal intensity in the hepatobiliary phase (HBP) and serum alpha-fetoprotein (AFP) levels, respectively.

Main finding: The only significant predictive factors of noncomplete response and short DFS were signal intensity heterogeneity in the HBP (adjusted odds ratio, 4.807; P = .048) and elevated serum AFP levels (≥30 ng/mL; adjusted hazard ratio, 2.916; P = .040), respectively.

Study details: This was a preliminary single-center retrospective study including 55 treatment-naive patients who underwent DEB-TACE for HCC.

Disclosures: The study was sponsored by the Bio & Medical Technology Development Program of the National Research Foundation funded by the Korean government. The authors reported no conflict of interests.

Source: Lee JY et al. Sci Rep. 2021 Dec 15. doi: 10.1038/s41598-021-01839-6.

Key clinical point: Compared with radiofrequency ablation (RFA), microwave ablation (MWA) effectuates better 1- and 2-year disease-free survival (DFS) along with a lower risk of major complications in patients with hepatocellular carcinoma (HCC).

Main finding: Although both ablation therapies led to a similar 2-year overall survival (P = .573), MWA achieved better 1-year DFS (79.7% vs 60.7%; P = .035) and 2-year DFS (72.5% vs 45.4%; P = .02) rates than RFA. Concurrently, MWA showed a lower rate of major complications than RFA (14% vs 29%; P = .043).

Study details: Findings are from a retrospective cohort study involving 150 patients with HCC, including treatment-naïve and recurrent HCC, who were treated with either RFA (n=100) or MWA (n=50).

Disclosures: The study was sponsored by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education. No conflict of interests was reported by the authors.

Source: Lee SK et al. J Clin Med. 2022 Jan 7. doi: 10.3390/jcm11020302.

Key clinical point: Compared with radiofrequency ablation (RFA), microwave ablation (MWA) effectuates better 1- and 2-year disease-free survival (DFS) along with a lower risk of major complications in patients with hepatocellular carcinoma (HCC).

Main finding: Although both ablation therapies led to a similar 2-year overall survival (P = .573), MWA achieved better 1-year DFS (79.7% vs 60.7%; P = .035) and 2-year DFS (72.5% vs 45.4%; P = .02) rates than RFA. Concurrently, MWA showed a lower rate of major complications than RFA (14% vs 29%; P = .043).

Study details: Findings are from a retrospective cohort study involving 150 patients with HCC, including treatment-naïve and recurrent HCC, who were treated with either RFA (n=100) or MWA (n=50).

Disclosures: The study was sponsored by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education. No conflict of interests was reported by the authors.

Source: Lee SK et al. J Clin Med. 2022 Jan 7. doi: 10.3390/jcm11020302.

Key clinical point: Compared with radiofrequency ablation (RFA), microwave ablation (MWA) effectuates better 1- and 2-year disease-free survival (DFS) along with a lower risk of major complications in patients with hepatocellular carcinoma (HCC).

Main finding: Although both ablation therapies led to a similar 2-year overall survival (P = .573), MWA achieved better 1-year DFS (79.7% vs 60.7%; P = .035) and 2-year DFS (72.5% vs 45.4%; P = .02) rates than RFA. Concurrently, MWA showed a lower rate of major complications than RFA (14% vs 29%; P = .043).

Study details: Findings are from a retrospective cohort study involving 150 patients with HCC, including treatment-naïve and recurrent HCC, who were treated with either RFA (n=100) or MWA (n=50).

Disclosures: The study was sponsored by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education. No conflict of interests was reported by the authors.

Source: Lee SK et al. J Clin Med. 2022 Jan 7. doi: 10.3390/jcm11020302.

Key clinical point: Compared with radiofrequency ablation (RFA), microwave ablation (MWA) effectuates better 1- and 2-year disease-free survival (DFS) along with a lower risk of major complications in patients with hepatocellular carcinoma (HCC).

Main finding: Although both ablation therapies led to a similar 2-year overall survival (P = .573), MWA achieved better 1-year DFS (79.7% vs 60.7%; P = .035) and 2-year DFS (72.5% vs 45.4%; P = .02) rates than RFA. Concurrently, MWA showed a lower rate of major complications than RFA (14% vs 29%; P = .043).

Study details: Findings are from a retrospective cohort study involving 150 patients with HCC, including treatment-naïve and recurrent HCC, who were treated with either RFA (n=100) or MWA (n=50).

Disclosures: The study was sponsored by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education. No conflict of interests was reported by the authors.

Source: Lee SK et al. J Clin Med. 2022 Jan 7. doi: 10.3390/jcm11020302.

Key clinical point: Compared with radiofrequency ablation (RFA), microwave ablation (MWA) effectuates better 1- and 2-year disease-free survival (DFS) along with a lower risk of major complications in patients with hepatocellular carcinoma (HCC).

Main finding: Although both ablation therapies led to a similar 2-year overall survival (P = .573), MWA achieved better 1-year DFS (79.7% vs 60.7%; P = .035) and 2-year DFS (72.5% vs 45.4%; P = .02) rates than RFA. Concurrently, MWA showed a lower rate of major complications than RFA (14% vs 29%; P = .043).

Study details: Findings are from a retrospective cohort study involving 150 patients with HCC, including treatment-naïve and recurrent HCC, who were treated with either RFA (n=100) or MWA (n=50).

Disclosures: The study was sponsored by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education. No conflict of interests was reported by the authors.

Source: Lee SK et al. J Clin Med. 2022 Jan 7. doi: 10.3390/jcm11020302.

Key clinical point: Compared with radiofrequency ablation (RFA), microwave ablation (MWA) effectuates better 1- and 2-year disease-free survival (DFS) along with a lower risk of major complications in patients with hepatocellular carcinoma (HCC).

Main finding: Although both ablation therapies led to a similar 2-year overall survival (P = .573), MWA achieved better 1-year DFS (79.7% vs 60.7%; P = .035) and 2-year DFS (72.5% vs 45.4%; P = .02) rates than RFA. Concurrently, MWA showed a lower rate of major complications than RFA (14% vs 29%; P = .043).

Study details: Findings are from a retrospective cohort study involving 150 patients with HCC, including treatment-naïve and recurrent HCC, who were treated with either RFA (n=100) or MWA (n=50).

Disclosures: The study was sponsored by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education. No conflict of interests was reported by the authors.

Source: Lee SK et al. J Clin Med. 2022 Jan 7. doi: 10.3390/jcm11020302.

Key clinical point: First-line radiofrequency ablation (RFA) is associated with worse long-term therapeutic outcomes for single periportal hepatocellular carcinoma (HCC) than for single nonperiportal HCC.

Main finding: At 1 and 5 years, periportal vs nonperiportal HCC was associated with significantly higher local tumor progression rates (15.7% and 46.9% vs 6.0% and 28.7%, respectively; P = .007) and worse overall survival rates (81.3% and 42.9% vs 99.3% and 78.1%, respectively; P < .0001).

Study details: The data come from a retrospective study involving 233 patients with HCC, either periportal (n=56) or nonperiportal (n=177), who underwent percutaneous RFA alone or combined with transarterial chemoembolization as first-line treatment.

Disclosures: The authors reported no funding source or conflict of interests.

Source: Cao S et al. Cancer Imaging. 2022 Jan 4. doi: 10.1186/s40644-021-00442-2.

Key clinical point: First-line radiofrequency ablation (RFA) is associated with worse long-term therapeutic outcomes for single periportal hepatocellular carcinoma (HCC) than for single nonperiportal HCC.

Main finding: At 1 and 5 years, periportal vs nonperiportal HCC was associated with significantly higher local tumor progression rates (15.7% and 46.9% vs 6.0% and 28.7%, respectively; P = .007) and worse overall survival rates (81.3% and 42.9% vs 99.3% and 78.1%, respectively; P < .0001).

Study details: The data come from a retrospective study involving 233 patients with HCC, either periportal (n=56) or nonperiportal (n=177), who underwent percutaneous RFA alone or combined with transarterial chemoembolization as first-line treatment.

Disclosures: The authors reported no funding source or conflict of interests.

Source: Cao S et al. Cancer Imaging. 2022 Jan 4. doi: 10.1186/s40644-021-00442-2.

Key clinical point: First-line radiofrequency ablation (RFA) is associated with worse long-term therapeutic outcomes for single periportal hepatocellular carcinoma (HCC) than for single nonperiportal HCC.

Main finding: At 1 and 5 years, periportal vs nonperiportal HCC was associated with significantly higher local tumor progression rates (15.7% and 46.9% vs 6.0% and 28.7%, respectively; P = .007) and worse overall survival rates (81.3% and 42.9% vs 99.3% and 78.1%, respectively; P < .0001).

Study details: The data come from a retrospective study involving 233 patients with HCC, either periportal (n=56) or nonperiportal (n=177), who underwent percutaneous RFA alone or combined with transarterial chemoembolization as first-line treatment.

Disclosures: The authors reported no funding source or conflict of interests.

Source: Cao S et al. Cancer Imaging. 2022 Jan 4. doi: 10.1186/s40644-021-00442-2.

Key clinical point: As initial treatment, hepatic arterial infusion chemotherapy (HAIC) effectuates a greater survival and radiological response than transarterial chemoembolization (TACE) among patients with infiltrative hepatocellular carcinoma (HCC).

Main finding: HIAC vs TACE led to a longer median overall survival (13.3 months vs 10.8 months; P = .043) and progression-free survival (7.8 months vs 4.0 months; P = .035) along with higher objective response (34.8% vs 11.8%; P = .001) and disease control (54.3% vs 36.8%; P = .028) rates.

Study details: Findings are from a retrospective real-world study including 160 adult patients with large infiltrative HCCs who underwent either HAIC (n=92) or TACE (n=68) as initial treatment.

Disclosures: The authors declared receiving no financial assistance for the study and having no potential conflict of interests.

Source: An C et al. Front Oncol. 2021 Dec 16. doi: 10.3389/fonc.2021.747496.

Key clinical point: As initial treatment, hepatic arterial infusion chemotherapy (HAIC) effectuates a greater survival and radiological response than transarterial chemoembolization (TACE) among patients with infiltrative hepatocellular carcinoma (HCC).

Main finding: HIAC vs TACE led to a longer median overall survival (13.3 months vs 10.8 months; P = .043) and progression-free survival (7.8 months vs 4.0 months; P = .035) along with higher objective response (34.8% vs 11.8%; P = .001) and disease control (54.3% vs 36.8%; P = .028) rates.

Study details: Findings are from a retrospective real-world study including 160 adult patients with large infiltrative HCCs who underwent either HAIC (n=92) or TACE (n=68) as initial treatment.

Disclosures: The authors declared receiving no financial assistance for the study and having no potential conflict of interests.

Source: An C et al. Front Oncol. 2021 Dec 16. doi: 10.3389/fonc.2021.747496.

Key clinical point: As initial treatment, hepatic arterial infusion chemotherapy (HAIC) effectuates a greater survival and radiological response than transarterial chemoembolization (TACE) among patients with infiltrative hepatocellular carcinoma (HCC).

Main finding: HIAC vs TACE led to a longer median overall survival (13.3 months vs 10.8 months; P = .043) and progression-free survival (7.8 months vs 4.0 months; P = .035) along with higher objective response (34.8% vs 11.8%; P = .001) and disease control (54.3% vs 36.8%; P = .028) rates.

Study details: Findings are from a retrospective real-world study including 160 adult patients with large infiltrative HCCs who underwent either HAIC (n=92) or TACE (n=68) as initial treatment.

Disclosures: The authors declared receiving no financial assistance for the study and having no potential conflict of interests.

Source: An C et al. Front Oncol. 2021 Dec 16. doi: 10.3389/fonc.2021.747496.

Key clinical point: Modified Response Evaluation Criteria in Solid Tumors (mRECIST)-determined objective response (OR) and early tumor shrinkage (ETS) may serve as independent prognostic factors for overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) on sorafenib monotherapy.

Main finding: OR assessed by mRECIST (adjusted hazard ratio [aHR], 0.32; P < .001) and ETS (aHR, 0.44; P < .001) were independent prognostic factors for OS. A longer median OS was shown by responders vs nonresponders (30.3 months vs 11.4 months; P < .001) and by patients with ETS ≥20% vs those with ETS <20% (22.1 months vs 11.4 months; P < .001).

Study details: This was a post hoc analysis of data from the phase 2 SORAMIC trial and included 115 patients with advanced HCC receiving sorafenib monotherapy.

Disclosures: The study was sponsored by Sirtex Medical and Bayer Healthcare. Some of the authors declared receiving personal fees and research grants from various sources including Bayer and Sirtex.

Source: Öcal O et al. Cancer Imaging. 2022 Jan 4. doi: 10.1186/s40644-021-00439-x.

Key clinical point: Modified Response Evaluation Criteria in Solid Tumors (mRECIST)-determined objective response (OR) and early tumor shrinkage (ETS) may serve as independent prognostic factors for overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) on sorafenib monotherapy.

Main finding: OR assessed by mRECIST (adjusted hazard ratio [aHR], 0.32; P < .001) and ETS (aHR, 0.44; P < .001) were independent prognostic factors for OS. A longer median OS was shown by responders vs nonresponders (30.3 months vs 11.4 months; P < .001) and by patients with ETS ≥20% vs those with ETS <20% (22.1 months vs 11.4 months; P < .001).

Study details: This was a post hoc analysis of data from the phase 2 SORAMIC trial and included 115 patients with advanced HCC receiving sorafenib monotherapy.

Disclosures: The study was sponsored by Sirtex Medical and Bayer Healthcare. Some of the authors declared receiving personal fees and research grants from various sources including Bayer and Sirtex.

Source: Öcal O et al. Cancer Imaging. 2022 Jan 4. doi: 10.1186/s40644-021-00439-x.

Key clinical point: Modified Response Evaluation Criteria in Solid Tumors (mRECIST)-determined objective response (OR) and early tumor shrinkage (ETS) may serve as independent prognostic factors for overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) on sorafenib monotherapy.

Main finding: OR assessed by mRECIST (adjusted hazard ratio [aHR], 0.32; P < .001) and ETS (aHR, 0.44; P < .001) were independent prognostic factors for OS. A longer median OS was shown by responders vs nonresponders (30.3 months vs 11.4 months; P < .001) and by patients with ETS ≥20% vs those with ETS <20% (22.1 months vs 11.4 months; P < .001).

Study details: This was a post hoc analysis of data from the phase 2 SORAMIC trial and included 115 patients with advanced HCC receiving sorafenib monotherapy.

Disclosures: The study was sponsored by Sirtex Medical and Bayer Healthcare. Some of the authors declared receiving personal fees and research grants from various sources including Bayer and Sirtex.

Source: Öcal O et al. Cancer Imaging. 2022 Jan 4. doi: 10.1186/s40644-021-00439-x.